BD Welcomes Vitor Roque as New Chief Financial Officer to Drive Strategic Growth

BD Appoints Vitor Roque as Chief Financial Officer

On May 7, 2026, BD (Becton, Dickinson and Company), a leader in global medical technology, announced the appointment of Vitor Roque as Chief Financial Officer (CFO). Roque, who has been serving as the interim CFO since December 2025, brings a wealth of experience and a deep understanding of the company's operations to the role.

With over 25 years of tenure at BD, Roque has held primary finance and operations positions throughout the organization. His most recent role prior to becoming interim CFO was Senior Vice President for Finance and Corporate Financial Planning and Analysis. In this capacity, he played a crucial role in steering BD’s global finance operations and successfully executed major strategic initiatives, including the early completion of the separation of BD's Biosciences Diagnostic Solutions business.

Tom Polen, the Chairman, CEO, and President of BD, expressed his enthusiasm about Roque's appointment, stating, “Following a comprehensive search process, it was clear that Vitor is the right leader to serve as BD's next CFO. He possesses the capabilities and industry insight that are vital as we strive to enhance our leadership pipeline.”

The CEO highlighted Roque's profound insight into BD’s business, showcasing his exceptional ability to translate strategy into tangible performance. This skill is paramount as the company aims to maintain a consistent execution framework while driving scalability. Roque's capability in strengthening financial performance has been recognized, and Polen is optimistic about Roque’s contribution to delivering the next phase of growth for the company.

In addition to his financial acumen, Roque holds significant institutional knowledge across BD’s diverse product portfolio and operates in various global markets. His extensive experience stems from his hands-on leadership approach and his time spent working in multiple countries, which has enriched his perspective on the cultural and regional dynamics that are critical for BD’s success as a globally recognized entity.

As he transitions into his new role, Roque remarked, “This is an important moment for BD, and I’m honored to step into this position as we accelerate our progress. After over two decades with the company, I foresee immense opportunities ahead, backed by a well-defined strategy that presents significant growth potential.” He emphasized the importance of a solid operational foundation, disciplined financial management, and focused execution to enhance shareholder value.

BD's purpose, reflected in Roque’s vision, is to advance healthcare worldwide. Roque emphasized the need to enhance clinical operations and care outcomes through innovation. This includes the introduction of transformative technologies and services aimed at optimizing healthcare delivery effectively.

With over 60,000 employees globally, BD is committed to creating a positive impact in healthcare. The company, recognized as one of the largest standalone medical technology companies, aims to drive continued innovation across medical essentials, connected care, biopharma systems, and interventional sectors. As they progress, BD works diligently to develop solutions that not only improve clinical efficiency but also foster safety and expand access to healthcare.

In conclusion, Vitor Roque's appointment as CFO not only enhances BD’s leadership team but also aligns with the company's broader vision of driving sustainable growth and value creation in the ever-evolving healthcare landscape. With Roque at the helm of the financial strategy, BD is well positioned to advance its mission of elevating global health standards.